Full face ingenol mebutate for actinic keratosis: patient perspective

Int J Dermatol. 2019 Jan;58(1):e6-e9. doi: 10.1111/ijd.14263. Epub 2018 Oct 9.

Authors

Eleni Anthony¹, Karyn Lun¹, Saxon D Smith^{2

3

4}

Affiliations

¹ Queensland Institute of Dermatology, Brisbane, Qld, Australia.
² The Dermatology and Skin Cancer Centre, Gosford, NSW, Australia.
³ Northern Clinical School, University of Sydney, Sydney, NSW, Australia.
⁴ Department of Dermatology, Royal North Shore Hospital, St Leonards, NSW, Australia.

PMID: 30302750
DOI: 10.1111/ijd.14263

No abstract available

Publication types

Evaluation Study
Letter

MeSH terms

Administration, Cutaneous
Adult
Aged
Aged, 80 and over
Diterpenes / administration & dosage*
Diterpenes / adverse effects
Drug Administration Schedule
Face
Female
Follow-Up Studies
Humans
Keratosis, Actinic / drug therapy*
Male
Middle Aged
Patient Reported Outcome Measures
Patient Satisfaction / statistics & numerical data
Quality of Life
Treatment Outcome

Substances

3-ingenyl angelate
Diterpenes